HOME >> MEDICINE >> NEWS
Results of exercise test may predict death in patients with coronary artery disease

Exercise capacity, as measured in terms of VO2max, is a powerful predictor of death in patients with coronary artery disease, not just patients with heart failure. That is the finding of Mayo Clinic research presented today at the American Heart Association's Scientific Sessions 2005 in Dallas.

VO2max is the maximum amount of oxygen a person can take in during exercise. In a VO2max study, a patient walks on a treadmill for about 5 to 15 minutes and breathes through a valve; the oxygen and carbon dioxide in the expired air are measured. Results are given in milliliters of oxygen per kilogram of body weight per minute (ml/kg/min).

"The best predictor of survival in cardiac patients is their capacity for exercise," says Thomas Allison, Ph.D., the lead author of the study, who is from Mayo Clinic in Rochester, Minn. "When we considered all of the measurable clinical variables -- such as whether they had bypass surgery or whether they have diabetes or high blood pressure -- the patient's capacity for exercise as measured by VO2max stood clear as the best predictor for 10-year survival."

In this study, the significance of low VO2max levels was examined in patients with coronary artery disease -- the top cause of death in the United States and often a precursor to a heart attack and heart failure.

A group of 282 patients, 17 percent of them women, underwent cardiopulmonary treadmill testing at the end of cardiac rehabilitation and were followed for an average of 9.8 years. The average age was 61 at the time of the test.

In the first two years there were few deaths, but after that mortality was significantly higher in patients with low VO2max. Fifty-five patients had a low VO2max (less than 18 ml/kg/min); at 10 years, almost half (42 percent) had died. Of the 227 patients who had a VO2max above or equal to 18 ml/kg/min, only 11.6 percent had died at the 10-year mark. Even after adjusting for age, sex and ventricular function, VO2ma
'"/>

Contact: Traci Klein
newsbureau@mayo.edu
507-284-5005, 507-284-251
Mayo Clinic
14-Nov-2005


Page: 1 2

Related medicine news :

1. Results of largest ever genome scan for autism out
2. Timely treatment of heart attacks: Results from the AMI-QUEBEC Study
3. Results of hospital performance measures do not always reflect patient outcomes
4. Results good for HER-2 positive breast cancer patients using trastuzumab
5. Results of clipping and coiling of aneurysms are similar over time
6. Results with newer bladeless LASIK equivalent to standard microkeratome LASIK
7. Traditional Chinese exercises may increase efficacy of flu vaccine
8. Even low levels of weekly exercise drive down blood pressure
9. Some women benefit more from exercise when emphasis is on health, not appearance
10. Strengthening exercises may slow progression of ALS
11. Research shows aerobic exercise helps maintain muscle in elderly

Post Your Comments:
(Date:6/19/2013)... The former internist for the St. Louis Rams ... as director of prevention and wellness at St. Luke’s ... encounter with a metabolic syndrome diagnosis and a happenstance ... that he credits with sparking the paradigm-shift that has ... , “The average medical student gets 30 minutes of ...
(Date:6/19/2013)... June 19, 2013 “We are proud to ... nothing else like it in the U.S.,” says Shaun Johnson, ... an effective and inexpensive solution to a very expensive problem, ... their koi fish,” he adds. , Each package of ... to fit the shape of any water garden or pond. ...
(Date:6/19/2013)... 2013 The producers of Viewpoints TV ... Arizona. The city is located in the center of ... shed its frontier image and become an affordable city to ... fifth-largest city in the United States with a workforce strong ... residents a low cost-of-living, friendly business environment and more than ...
(Date:6/19/2013)... the incidence of cancer is many fold higher in ... an inadequate understanding on how best to treat these ... occasionally included in clinical trials, those elderly patients who ... Thus, the broader elderly patient population is not well ... Elderly Task Force is now starting a new phase ...
(Date:6/19/2013)... June 19, 2013 The Cancer Support ... promise of cancer care for the whole patient with ... the Cancer Support Community. This inaugural event, held at ... Emanuel, MD., Ph.D., recognition of Congress members who have ... voices of patients and families currently engaged in the ...
Breaking Medicine News(10 mins):Health News:Plant-based Nutrition is Key to Health Transformation of St. Luke’s Hospital Director of Prevention and Wellness 2Health News:Plant-based Nutrition is Key to Health Transformation of St. Luke’s Hospital Director of Prevention and Wellness 3Health News:Viewpoints TV Announces June Air Dates for Phoenix, AZ 2Health News:EORTC study opens for elderly patients with HER-2 positive metastatic breast cancer 2Health News:Keeping the Promise of Cancer Care for the Whole Patient 2Health News:Keeping the Promise of Cancer Care for the Whole Patient 3
(Date:6/19/2013)... June 19, 2013 Amerivet Solutions, LLC ... all branches of government from Federal to Municipal, ... their facilities to include complex metal design and ... some very complex aluminum parts for the Defense ... our capabilities to service government contracts," states ...
(Date:6/19/2013)... ZIONA, Israel , June ... announced that results from a phase I study in ... in advanced Parkinson,s patients, of ND0612, were presented at ... Disorders. ND0612 is a proprietary levodopa/carbidopa liquid drug formula ... delivery patch that would maintain constant levodopa plasma concentrations. ...
(Date:6/19/2013)... 2013 /PRNewswire-iReach/ -- In its first major ... company dedicated to advancing development of the ... release drug therapies in patient disease populations ... the acquisition of Enzon Pharmaceutical,s PEGylation Linker ... product pipeline. Acquisition of this technology will ...
Breaking Medicine Technology:Amerivet Solutions Expands to Manufacture Complex Metal Designs 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 3Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 4
Cached News: